Showing results (71-80 of 211) with videos related to
Sort By:
Pageof 22
Breast Cancer Research and Treatment|June 27, 2022
Co-occurrence and metabolic biomarkers of sensory and motor subtypes of peripheral neuropathy from paclitaxelCiao-Sin Chen, Ellen M Lavoie Smith, Kathleen A Stringer, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 23, 2022
Lack of association of CYP2B6 pharmacogenetics with cyclophosphamide toxicity in patients with cancerMary Hwang, Sarah Medley, Faisal Shakeel, et al.JCO Precision Oncology|January 31, 2025
Quantitation of Plasma Proteins to Predict Taxane-Induced Peripheral NeuropathyNam Nguyen-Hoang, Yaping Liu, N Lynn Henry, et al.Journal of Oncology Practice|May 23, 2018
Comparison of Nine Tools for Screening Drug-Drug Interactions of Oral OncolyticsLauren A Marcath, Jingyue Xi, Emily K Hoylman, et al.Journal of the National Comprehensive Cancer Network : JNCCN|February 10, 2009
Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?Michaela J Higgins, James M Rae, David A Flockhart, et al.Breast Cancer Research and Treatment|March 30, 2012
Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivationMatthew J Sikora, Viktoriya Strumba, Marc E Lippman, et al.Journal of the Peripheral Nervous System : JPNS|October 13, 2022
Wearables, sensors, and smart devices for the detection and monitoring of chemotherapy-induced peripheral neurotoxicity: Systematic review and directions for future researchElisa Mantovani, Florenc Demrozi, Daniel L Hertz, et al.Pharmacogenomics|October 6, 2021
SLCO1B3 polymorphisms and clinical outcomes in kidney transplant recipients receiving mycophenolateLauren Schumacher, Fang Fang, Kelley M Kidwell, et al.Breast Cancer Research and Treatment|April 17, 2016
The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancerCameron P Capper, José M Larios, Matthew J Sikora, et al.Breast Cancer Research and Treatment|September 28, 2006
MDA-MB-435 cells are derived from M14 melanoma cells--a loss for breast cancer, but a boon for melanoma researchJames M Rae, Chad J Creighton, Jeanne M Meck, et al.Pageof 22